1. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Issue 10068 (4th February 2017) Authors: Durie, Brian G M; Hoering, Antje; Abidi, Muneer H; Rajkumar, S Vincent; Epstein, Joshua; Kahanic, Stephen P; Thakuri, Mohan; Reu, Frederic; Reynolds, Christopher M; Sexton, Rachael; Orlowski, Robert Z; Barlogie, Bart; Dispenzieri, Angela Journal: Lancet Issue: Volume 389:Issue 10068(2017) Page Start: 519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. Issue 1 (December 2016) Authors: Luo, Hongmei; Qin, Yu; Reu, Frederic; Ye, Sujuan; Dai, Yang; Huang, Jingcao; Wang, Fangfang; Zhang, Dan; Pan, Ling; Zhu, Huanling; Wu, Yu; Niu, Ting; Xiao, Zhijian; Zheng, Yuhuan; Liu, Ting Journal: Journal of hematology & oncology Issue: Volume 9:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Issue 2 (December 2016) Authors: Baz, Rachid; Zonder, Jeffrey; Gasparetto, Cristina; Reu, Frederic; Strout, Vincent Journal: Oncology and therapy Issue: Volume 4:Issue 2(2016) Page Start: 287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗